Table 2.

Expression pattern of MMR protein and histopathological characteristics of CRC

			A	B	C	D	E	F	G	H	I	J	P
		n.	38	1	29	22	1	1	4	7	9	3
Mucinous component	Absent	n	26	1	13	7	0	0	2	5	4	2	0.353
		%	68	100	45	32	0	0	50.	72	44	67
	<10%	n	3	0	3	1	0	0	1	0	2	0
		%	8	0	10	5	0	0	25.	0	22	0
	10-50%	n	3	0	6	4	1	0	1	1	1	1
		%	8	0	21	18	100	0	25	14	11.	33
	≥50%	n	6	0	7	10	0	1	0	1	2	0
		%	16	0	24	50	0	100	0	14	22	0
Signet ring component	A	n	36	1	28	19	1	0	4	6	9	3	0.041*
		%	95	100	97	86	100	0	100	86	100	100
	P	n	2	0	1	3	0	1	0	1	0	0
		%	5	0	3	14	0	100	0	14	0	0
TIL	Absent	n	27	0	15	8	1	1	0	3	2	1	0.012*
		%	71	0	52	36	100	100	0	43	22	33
	Mild	n	11	1	14	14	0	0	4	3	7	2
		%	29	100	48	64	0	0	100	43	78	67
	Marked	n	0	0	0	0	0	0	0	1	0	0
		%	0	0	0	0	0	0	0	14	0	0
PTL	Absent	n	38	0	26	18	1	1	4	5	9	2	0.009*
		%	100	0	90	82	100	100	100	71	100	67
	Present	n	0	1	3	4	0	0	0	2	0	1
		%	0	100	10	18	0	0	0	29	0	33
Necrosis	Absent	n	10	0	11	2	0	0	1	2	4	0	0.172
		%	26	0	38	9	0	0	25	29	44	0
	Focal	n	23	0	15	13	1	1	3	5	5	3
		%	61	0	52	59	100	100	75	71	56	100
	Diffuse	n	5	1	3	7	0	0	0	0	0	0
		%	13	100	10	32	0	0	0	0	0	0

TIL: tumour infiltrating lymphocyte; PTL: peritumoral lesion; A: no loss of expression of any marker; B: loss of expression of all markers; C: loss of expression of both MLH, and PMS2; D: loss of expression of both MSH2, and MSH6; E: loss of expression of both of MSH6, and PMS2; F: loss of expression of both of MLH, and MSH2; G: isolated loss of expression of MLH; H: isolated loss of expression of MSH2; I: isolated loss of expression of MSH6; J: isolated loss of expression of PMS2.